Results 291 to 297 of about 53,113 (297)

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

New England Journal of Medicine, 2020
, Shukui Qin, Masafumi Ikeda
exaly  

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

Nature Medicine, 2019
Ryan J Sullivan, Hussein A Tawbi, Matthew J Wongchenko   +2 more
exaly  

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Lancet, The, 2017
Arjun V Balar, Matthew D Galsky, Jonathan E Rosenberg   +2 more
exaly  

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Lancet, The, 2018
Thomas Powles, Michiel S Van Der Heijden, Nicholas J Vogelzang   +2 more
exaly  

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Lancet, The, 2019
Brian I Rini, Thomas Powles, Michael B Atkins   +2 more
exaly  

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Lancet Respiratory Medicine,the, 2019
Makoto Nishio, Federico Cappuzzo, Daniil Stroyakovskiy   +2 more
exaly  

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Nature Communications, 2016
Johanna C Bendell, Konstanty Korski, Suzanne Jones   +2 more
exaly